Skip to content
2000
Volume 31, Issue 20
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Scutellarein, a flavone found in the perennial herb , has a wide range of pharmacological actions, such as antioxidant, anti-inflammatory, and neuroprotective. Increasing evidence has emphasized the developing significance of scutellarein in several neurological illnesses, such as Alzheimer's and Parkinson's disease, cerebral ischemia, and neuroblastoma. This review is centered on the molecular processes that underlie the neuroprotective properties of scutellarein in various neurological disorders, as indicated by recent pre-clinical research. Furthermore, it critically examines the potential challenges and advantages of scutellarein inclusion within the range of treatments for neurological disorders.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128336901241125092132
2025-01-07
2025-12-06

  • From This Site

    /content/journals/cpd/10.2174/0113816128336901241125092132
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FeiginV.L. NicholsE. AlamT. BannickM.S. BeghiE. BlakeN. CulpepperW.J. DorseyE.R. ElbazA. EllenbogenR.G. FisherJ.L. FitzmauriceC. GiussaniG. GlennieL. JamesS.L. JohnsonC.O. KassebaumN.J. LogroscinoG. MarinB. Mountjoy-VenningW.C. NguyenM. Ofori-AsensoR. PatelA.P. PiccininniM. RothG.A. SteinerT.J. StovnerL.J. SzoekeC.E.I. TheadomA. VollsetS.E. WallinM.T. WrightC. ZuntJ.R. AbbasiN. Abd-AllahF. AbdelalimA. AbdollahpourI. AboyansV. AbrahaH.N. AcharyaD. AdamuA.A. AdebayoO.M. AdeoyeA.M. AdsuarJ.C. AfaridehM. AgrawalS. AhmadiA. AhmedM.B. AichourA.N. AichourI. AichourM.T.E. AkinyemiR.O. AkseerN. Al-EyadhyA. Al-Shahi SalmanR. AlahdabF. AleneK.A. AljunidS.M. AltirkawiK. Alvis-GuzmanN. AnberN.H. AntonioC.A.T. ArablooJ. AremuO. ÄrnlövJ. AsayeshH. AsgharR.J. AtalayH.T. AwasthiA. Ayala QuintanillaB.P. AyukT.B. BadawiA. BanachM. BanoubJ.A.M. BarbozaM.A. Barker-ColloS.L. BärnighausenT.W. BauneB.T. BediN. BehzadifarM. BehzadifarM. BéjotY. BekeleB.B. BelachewA.B. BennettD.A. BensenorI.M. BerhaneA. BeuranM. BhattacharyyaK. BhuttaZ.A. BiadgoB. BijaniA. BililignN. Bin SayeedM.S. BlazesC.K. BrayneC. ButtZ.A. Campos-NonatoI.R. Cantu-BritoC. CarM. CárdenasR. CarreroJ.J. CarvalhoF. Castañeda-OrjuelaC.A. CastroF. Catalá-LópezF. CerinE. ChaiahY. ChangJ-C. ChatziralliI. ChiangP.P-C. ChristensenH. ChristopherD.J. CooperC. CortesiP.A. CostaV.M. CriquiM.H. CroweC.S. DamascenoA.A.M. DaryaniA. De la Cruz-GóngoraV. De la HozF.P. De LeoD. DemozG.T. DeribeK. DharmaratneS.D. DiazD. DinberuM.T. DjalaliniaS. DokuD.T. DubeyM. DubljaninE. DukenE.E. EdvardssonD. El-KhatibZ. EndresM. EndriesA.Y. EskandariehS. EsteghamatiA. EsteghamatiS. FarhadiF. FaroA. FarzadfarF. FarzaeiM.H. FatimaB. FereshtehnejadS-M. FernandesE. FeyissaG.T. FilipI. FischerF. FukumotoT. GanjiM. GankpeF.G. Garcia-GordilloM.A. GebreA.K. GebremichaelT.G. GelawB.K. GeleijnseJ.M. GeremewD. GezaeK.E. Ghasemi-KasmanM. GideyM.Y. GillP.S. GillT.K. GirmaE.T. GnedovskayaE.V. GoulartA.C. GradaA. GrossoG. GuoY. GuptaR. GuptaR. HaagsmaJ.A. HagosT.B. Haj-MirzaianA. Haj-MirzaianA. HamadehR.R. HamidiS. HankeyG.J. HaoY. HaroJ.M. HassankhaniH. HassenH.Y. HavmoellerR. HayS.I. HegazyM.I. HeidariB. HenokA. HeydarpourF. HoangC.L. HoleM.K. Homaie RadE. HosseiniS.M. HuG. IgumborE.U. IlesanmiO.S. IrvaniS.S.N. IslamS.M.S. JakovljevicM. JavanbakhtM. JhaR.P. JobanputraY.B. JonasJ.B. JozwiakJ.J. JürissonM. KahsayA. KalaniR. KalkondeY. KamilT.A. KanchanT. KaramiM. KarchA. KarimiN. KasaeianA. KassaT.D. KassaZ.Y. KaulA. KefaleA.T. KeiyoroP.N. KhaderY.S. KhafaieM.A. KhalilI.A. KhanE.A. KhangY-H. KhazaieH. KiadaliriA.A. KiirithioD.N. KimA.S. KimD. KimY-E. KimY.J. KisaA. KokuboY. KoyanagiA. KrishnamurthiR.V. Kuate DefoB. Kucuk BicerB. KumarM. LaceyB. LafranconiA. LansinghV.C. LatifiA. LeshargieC.T. LiS. LiaoY. LinnS. LoW.D. LopezJ.C.F. LorkowskiS. LotufoP.A. LucasR.M. LuneviciusR. MackayM.T. MahotraN.B. MajdanM. MajdzadehR. MajeedA. MalekzadehR. MaltaD.C. ManafiN. MansourniaM.A. MantovaniL.G. MärzW. Mashamba-ThompsonT.P. MassenburgB.B. MateK.K.V. McAlindenC. McGrathJ.J. MehtaV. MeierT. MelesH.G. MeleseA. MemiahP.T.N. MemishZ.A. MendozaW. MengistuD.T. MengistuG. MeretojaA. MeretojaT.J. MestrovicT. MiazgowskiB. MiazgowskiT. MillerT.R. MiniG.K. MirrakhimovE.M. MoazenB. MohajerB. Mohammad Gholi MezerjiN. MohammadiM. Mohammadi-KhanaposhtaniM. MohammadibakhshR. Mohammadnia-AfrouziM. MohammedS. MohebiF. MokdadA.H. MonastaL. MondelloS. MoodleyY. MoosazadehM. MoradiG. Moradi-LakehM. MoradinazarM. MoragaP. Moreno VelásquezI. MorrisonS.D. MousaviS.M. MuhammedO.S. MuruetW. MusaK.I. MustafaG. NaderiM. NagelG. NaheedA. NaikG. NajafiF. NangiaV. NegoiI. NegoiR.I. NewtonC.R.J. NgunjiriJ.W. NguyenC.T. NguyenL.H. NingrumD.N.A. NirayoY.L. NixonM.R. NorrvingB. NoubiapJ.J. Nourollahpour ShiadehM. NyasuluP.S. OgahO.S. OhI-H. OlagunjuA.T. OlagunjuT.O. OlivaresP.R. OnwujekweO.E. OrenE. OwolabiM.O. PaM. PakpourA.H. PanW-H. Panda-JonasS. PandianJ.D. PatelS.K. PereiraD.M. PetzoldM. PillayJ.D. PiradovM.A. PolanczykG.V. PolinderS. PostmaM.J. PoultonR. PoustchiH. PrakashS. PrakashV. QorbaniM. RadfarA. RafayA. RafieiA. RahimF. Rahimi-MovagharV. RahmanM. RahmanM.H.U. RahmanM.A. RajatiF. RamU. RantaA. RawafD.L. RawafS. ReinigN. ReisC. RenzahoA.M.N. ResnikoffS. RezaeianS. RezaiM.S. Rios GonzálezC.M. RobertsN.L.S. RoeverL. RonfaniL. RoroE.M. RoshandelG. RostamiA. SabbaghP. SaccoR.L. SachdevP.S. SaddikB. SafariH. Safari-FaramaniR. SafiS. SafiriS. SagarR. SahathevanR. SahebkarA. SahraianM.A. SalamatiP. Salehi ZahabiS. SalimiY. SamyA.M. SanabriaJ. SantosI.S. Santric MilicevicM.M. SarrafzadeganN. SartoriusB. SarviS. SathianB. SatpathyM. SawantA.R. SawhneyM. SchneiderI.J.C. SchöttkerB. SchwebelD.C. SeedatS. SepanlouS.G. ShabaninejadH. ShafieesabetA. ShaikhM.A. ShakirR.A. Shams-BeyranvandM. ShamsizadehM. SharifM. Sharif-AlhoseiniM. SheJ. SheikhA. ShethK.N. ShigematsuM. ShiriR. ShirkoohiR. ShiueI. SiabaniS. SiddiqiT.J. SigfusdottirI.D. SigurvinsdottirR. SilberbergD.H. SilvaJ.P. SilveiraD.G.A. SinghJ.A. SinhaD.N. SkiadaresiE. SmithM. SobaihB.H. SobhaniS. SoofiM. SoyiriI.N. SposatoL.A. SteinD.J. SteinM.B. StokesM.A. SufiyanM.B. SykesB.L. SylajaP.N. Tabarés-SeisdedosR. Te AoB.J. Tehrani-BanihashemiA. TemsahM-H. TemsahO. ThakurJ.S. ThriftA.G. Topor-MadryR. Tortajada-GirbésM. Tovani-PaloneM.R. TranB.X. TranK.B. TruelsenT.C. TsadikA.G. Tudor CarL. UkwajaK.N. UllahI. UsmanM.S. UthmanO.A. ValdezP.R. VasankariT.J. VasanthanR. VeisaniY. VenketasubramanianN. ViolanteF.S. VlassovV. VosoughiK. VuG.T. VujcicI.S. WagnewF.S. WaheedY. WangY-P. WeiderpassE. WeissJ. WhitefordH.A. WijeratneT. WinklerA.S. WiysongeC.S. WolfeC.D.A. XuG. YadollahpourA. YamadaT. YanoY. YaseriM. YatsuyaH. YimerE.M. YipP. YismaE. YonemotoN. YousefifardM. YuC. ZaidiZ. ZamanS.B. ZamaniM. ZandianH. ZareZ. ZhangY. ZodpeyS. NaghaviM. MurrayC.J.L. VosT. Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the global burden of disease study 2016.Lancet Neurol.201918545948010.1016/S1474‑4422(18)30499‑X30879893
     [Google Scholar]
  2. MurrayC.J.L. VosT. LozanoR. NaghaviM. FlaxmanA.D. MichaudC. EzzatiM. ShibuyaK. SalomonJ.A. AbdallaS. AboyansV. AbrahamJ. AckermanI. AggarwalR. AhnS.Y. AliM.K. AlMazroaM.A. AlvaradoM. AndersonH.R. AndersonL.M. AndrewsK.G. AtkinsonC. BaddourL.M. BahalimA.N. Barker-ColloS. BarreroL.H. BartelsD.H. BasáñezM-G. BaxterA. BellM.L. BenjaminE.J. BennettD. BernabéE. BhallaK. BhandariB. BikbovB. AbdulhakA.B. BirbeckG. BlackJ.A. BlencoweH. BloreJ.D. BlythF. BolligerI. BonaventureA. BoufousS. BourneR. BoussinesqM. BraithwaiteT. BrayneC. BridgettL. BrookerS. BrooksP. BrughaT.S. Bryan-HancockC. BucelloC. BuchbinderR. BuckleG. BudkeC.M. BurchM. BurneyP. BursteinR. CalabriaB. CampbellB. CanterC.E. CarabinH. CarapetisJ. CarmonaL. CellaC. CharlsonF. ChenH. ChengA.T-A. ChouD. ChughS.S. CoffengL.E. ColanS.D. ColquhounS. ColsonK.E. CondonJ. ConnorM.D. CooperL.T. CorriereM. CortinovisM. de VaccaroK.C. CouserW. CowieB.C. CriquiM.H. CrossM. DabhadkarK.C. DahiyaM. DahodwalaN. Damsere-DerryJ. DanaeiG. DavisA. LeoD.D. DegenhardtL. DellavalleR. DelossantosA. DenenbergJ. DerrettS. Des JarlaisD.C. DharmaratneS.D. DheraniM. Diaz-TorneC. DolkH. DorseyE.R. DriscollT. DuberH. EbelB. EdmondK. ElbazA. AliS.E. ErskineH. ErwinP.J. EspindolaP. EwoigbokhanS.E. FarzadfarF. FeiginV. FelsonD.T. FerrariA. FerriC.P. FèvreE.M. FinucaneM.M. FlaxmanS. FloodL. ForemanK. ForouzanfarM.H. FowkesF.G.R. FransenM. FreemanM.K. GabbeB.J. GabrielS.E. GakidouE. GanatraH.A. GarciaB. GaspariF. GillumR.F. GmelG. Gonzalez-MedinaD. GosselinR. GraingerR. GrantB. GroegerJ. GuilleminF. GunnellD. GuptaR. HaagsmaJ. HaganH. HalasaY.A. HallW. HaringD. HaroJ.M. HarrisonJ.E. HavmoellerR. HayR.J. HigashiH. HillC. HoenB. HoffmanH. HotezP.J. HoyD. HuangJ.J. IbeanusiS.E. JacobsenK.H. JamesS.L. JarvisD. JasrasariaR. JayaramanS. JohnsN. JonasJ.B. KarthikeyanG. KassebaumN. KawakamiN. KerenA. KhooJ-P. KingC.H. KnowltonL.M. KobusingyeO. KorantengA. KrishnamurthiR. LadenF. LallooR. LaslettL.L. LathleanT. LeasherJ.L. LeeY.Y. LeighJ. LevinsonD. LimS.S. LimbE. LinJ.K. LipnickM. LipshultzS.E. LiuW. LoaneM. OhnoS.L. LyonsR. MabweijanoJ. MacIntyreM.F. MalekzadehR. MallingerL. ManivannanS. MarcenesW. MarchL. MargolisD.J. MarksG.B. MarksR. MatsumoriA. MatzopoulosR. MayosiB.M. McAnultyJ.H. McDermottM.M. McGillN. McGrathJ. Medina-MoraM.E. MeltzerM. MemishZ.A. MensahG.A. MerrimanT.R. MeyerA-C. MiglioliV. MillerM. MillerT.R. MitchellP.B. MockC. MocumbiA.O. MoffittT.E. MokdadA.A. MonastaL. MonticoM. Moradi-LakehM. MoranA. MorawskaL. MoriR. MurdochM.E. MwanikiM.K. NaidooK. NairM.N. NaldiL. NarayanK.M.V. NelsonP.K. NelsonR.G. NevittM.C. NewtonC.R. NolteS. NormanP. NormanR. O’DonnellM. O’HanlonS. OlivesC. OmerS.B. OrtbladK. OsborneR. OzgedizD. PageA. PahariB. PandianJ.D. RiveroA.P. PattenS.B. PearceN. PadillaR.P. Perez-RuizF. PericoN. PesudovsK. PhillipsD. PhillipsM.R. PierceK. PionS. PolanczykG.V. PolinderS. PopeC.A.III PopovaS. PorriniE. PourmalekF. PrinceM. PullanR.L. RamaiahK.D. RanganathanD. RazaviH. ReganM. RehmJ.T. ReinD.B. RemuzziG. RichardsonK. RivaraF.P. RobertsT. RobinsonC. De LeònF.R. RonfaniL. RoomR. RosenfeldL.C. RushtonL. SaccoR.L. SahaS. SampsonU. Sanchez-RieraL. SanmanE. SchwebelD.C. ScottJ.G. Segui-GomezM. ShahrazS. ShepardD.S. ShinH. ShivakotiR. SilberbergD. SinghD. SinghG.M. SinghJ.A. SingletonJ. SleetD.A. SliwaK. SmithE. SmithJ.L. StapelbergN.J.C. SteerA. SteinerT. StolkW.A. StovnerL.J. SudfeldC. SyedS. TamburliniG. TavakkoliM. TaylorH.R. TaylorJ.A. TaylorW.J. ThomasB. ThomsonW.M. ThurstonG.D. TleyjehI.M. TonelliM. TowbinJ.A. TruelsenT. TsilimbarisM.K. UbedaC. UndurragaE.A. van der WerfM.J. van OsJ. VavilalaM.S. VenketasubramanianN. WangM. WangW. WattK. WeatherallD.J. WeinstockM.A. WeintraubR. WeisskopfM.G. WeissmanM.M. WhiteR.A. WhitefordH. WiebeN. WiersmaS.T. WilkinsonJ.D. WilliamsH.C. WilliamsS.R.M. WittE. WolfeF. WoolfA.D. WulfS. YehP-H. ZaidiA.K.M. ZhengZ-J. ZoniesD. LopezA.D. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: A systematic analysis for the global burden of disease study 2010.Lancet201238098592197222310.1016/S0140‑6736(12)61689‑423245608
     [Google Scholar]
  3. GaskinJ. GomesJ. DarshanS. KrewskiD. Burden of neurological conditions in Canada.Neurotoxicology20176121010.1016/j.neuro.2016.05.00127153747
     [Google Scholar]
  4. MaherP. The potential of flavonoids for the treatment of neurodegenerative diseases.Int. J. Mol. Sci.20192012305610.3390/ijms2012305631234550
     [Google Scholar]
  5. CushnieT.P.T. LambA.J. Antimicrobial activity of flavonoids.Int. J. Antimicrob. Agents200526534335610.1016/j.ijantimicag.2005.09.00216323269
     [Google Scholar]
  6. MISHRAS.H. Traditional bitter medicinal plant Kulang.J. Integr. Med.201086510524
     [Google Scholar]
  7. ZhangJ.L. CheQ.M. LiS.Z. ZhouT.H. Study on metabolism of scutellarin in rats by HPLC-MS and HPLC-NMR.J. Asian Nat. Prod. Res.20035424925610.1080/102860203100010585814604233
     [Google Scholar]
  8. CheQ. ChenY. PanL. Scutellarein’s pharmacokinetics in rats.Zhongguo Xin Yao Zazhi200615181558
     [Google Scholar]
  9. Wen-zhengJu. JU Determination of scutellarin in human plasma by LC-MS method and its clinical pharmacokinetics in Chinese healthy volunteers.CJCP2005103298
     [Google Scholar]
  10. FeiginV.L. AbajobirA.A. AbateK.H. Abd-AllahF. AbdulleA.M. AberaS.F. AbyuG.Y. AhmedM.B. AichourA.N. AichourI. AichourM.T.E. AkinyemiR.O. AlabedS. Al-RaddadiR. Alvis-GuzmanN. AmareA.T. AnsariH. AnwariP. ÄrnlövJ. AsayeshH. AsgedomS.W. AteyT.M. Avila-BurgosL. FrinelE. AvokpahoG.A. AzarpazhoohM.R. BaracA. BarbozaM. Barker-ColloS.L. BärnighausenT. BediN. BeghiE. BennettD.A. BensenorI.M. BerhaneA. BetsuB.D. BhaumikS. BirlikS.M. BiryukovS. BoneyaD.J. BultoL.N.B. CarabinH. CaseyD. Castañeda-OrjuelaC.A. Catalá-LópezF. ChenH. ChitheerA.A. ChowdhuryR. ChristensenH. DandonaL. DandonaR. de VeberG.A. DharmaratneS.D. DoH.P. DokovaK. DorseyE.R. EllenbogenR.G. EskandariehS. FarvidM.S. FereshtehnejadS-M. FischerF. ForemanK.J. GeleijnseJ.M. GillumR.F. GiussaniG. GoldbergE.M. GonaP.N. GoulartA.C. GugnaniH.C. GuptaR. HachinskiV. GuptaR. HamadehR.R. HambisaM. HankeyG.J. HareriH.A. HavmoellerR. HayS.I. HeydarpourP. HotezP.J. JakovljevicM.M.B. JavanbakhtM. JeemonP. JonasJ.B. KalkondeY. KandelA. KarchA. KasaeianA. KastorA. KeiyoroP.N. KhaderY.S. KhalilI.A. KhanE.A. KhangY-H. TawfihA. KhojaA. KhubchandaniJ. KulkarniC. KimD. KimY.J. KivimakiM. KokuboY. KosenS. KravchenkoM. KrishnamurthiR.V. DefoB.K. KumarG.A. KumarR. KyuH.H. LarssonA. LavadosP.M. LiY. LiangX. LibenM.L. LoW.D. LogroscinoG. LotufoP.A. LoyC.T. MackayM.T. El RazekH.M.A. El RazekM.M.A. MajeedA. MalekzadehR. ManhertzT. MantovaniL.G. MassanoJ. MazidiM. McAlindenC. MehataS. MehndirattaM.M. MemishZ.A. MendozaW. MengistieM.A. MensahG.A. MeretojaA. MezgebeH.B. MillerT.R. MishraS.R. IbrahimN.M. MohammadiA. MohammedK.E. MohammedS. MokdadA.H. Moradi-LakehM. VelasquezI.M. MusaK.I. NaghaviM. NgunjiriJ.W. NguyenC.T. NguyenG. Le NguyenQ. NguyenT.H. NicholsE. NingrumD.N.A. NongV.M. NorrvingB. NoubiapJ.J.N. OgboF.A. OwolabiM.O. PandianJ.D. ParmarP.G. PereiraD.M. PetzoldM. PhillipsM.R. PiradovM.A. PoultonR.G. PourmalekF. QorbaniM. RafayA. RahmanM. RahmanM.H.U. RaiR.K. RajsicS. RantaA. RawafS. RenzahoA.M.N. RezaiM.S. RothG.A. RoshandelG. RubagottiE. SachdevP. SafiriS. SahathevanR. SahraianM.A. SamyA.M. SantaluciaP. SantosI.S. SartoriusB. SatpathyM. SawhneyM. SaylanM.I. SepanlouS.G. ShaikhM.A. ShakirR. ShamsizadehM. ShethK.N. ShigematsuM. ShomanH. SilvaD.A.S. SmithM. SobngwiE. SposatoL.A. StanawayJ.D. SteinD.J. SteinerT.J. StovnerL.J. AbdulkaderR.S. EI SzoekeC. Tabarés-SeisdedosR. TanneD. TheadomA.M. ThriftA.G. TirschwellD.L. Topor-MadryR. TranB.X. TruelsenT. TuemK.B. UkwajaK.N. UthmanO.A. VarakinY.Y. VasankariT. VenketasubramanianN. VlassovV.V. WadiloF. WakayoT. WallinM.T. WeiderpassE. WestermanR. WijeratneT. WiysongeC.S. WolduM.A. WolfeC.D.A. XavierD. XuG. YanoY. YimamH.H. YonemotoN. YuC. ZaidiZ. El Sayed ZakiM. ZuntJ.R. MurrayC.J.L. VosT. Global, regional, and national burden of neurological disorders during 1990–2015: A systematic analysis for the global burden of disease study 2015.Lancet Neurol.2017161187789710.1016/S1474‑4422(17)30299‑528931491
     [Google Scholar]
  11. KhanR.S. AhmedM.R. KhalidB. MahmoodA. HassanR. Biomarker detection of neurological disorders through spectroscopy analysis.IDMJAR2018411910.15713/ins.idmjar.86
     [Google Scholar]
  12. FeiginV.L. VosT. AlahdabF. AmitA.M.L. BärnighausenT.W. BeghiE. BeheshtiM. ChavanP.P. CriquiM.H. DesaiR. Dhamminda DharmaratneS. DorseyE.R. Wilder EaganA. ElgendyI.Y. FilipI. GiampaoliS. GiussaniG. Hafezi-NejadN. HoleM.K. IkedaT. Owens JohnsonC. KalaniR. KhatabK. KhubchandaniJ. KimD. KoroshetzW.J. KrishnamoorthyV. KrishnamurthiR.V. LiuX. LoW.D. LogroscinoG. MensahG.A. MillerT.R. MohammedS. MokdadA.H. Moradi-LakehM. MorrisonS.D. ShivamurthyV.K.N. NaghaviM. NicholsE. NorrvingB. OdellC.M. PupilloE. RadfarA. RothG.A. ShafieesabetA. SheikhA. SheikhbahaeiS. ShinJ.I. SinghJ.A. SteinerT.J. StovnerL.J. WallinM.T. WeissJ. WuC. ZuntJ.R. AdelsonJ.D. MurrayC.J.L. Burden of neurological disorders across the US from 1990-2017: A global burden of disease study.JAMA Neurol.202178216517610.1001/jamaneurol.2020.415233136137
     [Google Scholar]
  13. KellyR.R. SidlesS.J. LaRueA.C. Effects of neurological disorders on bone health.Front. Psychol.20201161236610.3389/fpsyg.2020.61236633424724
     [Google Scholar]
  14. GubertC. KongG. RenoirT. HannanA.J. Exercise, diet and stress as modulators of gut microbiota: Implications for neurodegenerative diseases.Neurobiol. Dis.202013410462110.1016/j.nbd.2019.10462131628992
     [Google Scholar]
  15. Cano-LópezI. HampelK.G. GarcésM. VillanuevaV. González-BonoE. Quality of life in drug-resistant epilepsy: Relationships with negative affectivity, memory, somatic symptoms and social support.J. Psychosom. Res.2018114313710.1016/j.jpsychores.2018.09.00130314576
     [Google Scholar]
  16. McGinleyM.P. GoldschmidtC.H. Rae-GrantA.D. Diagnosis and treatment of multiple sclerosis: A review.JAMA2021325876577910.1001/jama.2020.2685833620411
     [Google Scholar]
  17. BoardP.P.T.E. Neuroblastoma Treatment (PDQ®).PDQ Cancer Information Summaries.National Cancer InstituteUS2024
     [Google Scholar]
  18. FrankC. ChiuR. LeeJ. Parkinson disease primer, part 2: Management of motor and nonmotor symptoms.Can. Fam. Physician2023692919610.46747/cfp.69029136813521
     [Google Scholar]
  19. WalbertT. StecN.E. Palliative care in brain tumors.Handb. Clin. Neurol.2023191698010.1016/B978‑0‑12‑824535‑4.00011‑236599516
     [Google Scholar]
  20. SyedW. QadhiO.A. BarasheedA. AlZahraniE. Basil A Al-RawiM. Evaluation of knowledge of risk factors and warning signs of stroke - An observational study among future health care professionals.Front. Public Health202311113111010.3389/fpubh.2023.113111036969679
     [Google Scholar]
  21. TaxirovichA.S. The main etiological factors, methods of prevention and treatment of meningitis.IJST202322141148
     [Google Scholar]
  22. PlessA. WareD. SagguS. RehmanH. MorganJ. WangQ. Understanding neuropsychiatric symptoms in Alzheimer’s disease: Challenges and advances in diagnosis and treatment.Front. Neurosci.202317126377110.3389/fnins.2023.126377137732300
     [Google Scholar]
  23. HowlettJ.R. NelsonL.D. SteinM.B. Mental health consequences of traumatic brain injury.Biol. Psychiatry202291541342010.1016/j.biopsych.2021.09.02434893317
     [Google Scholar]
  24. AllinquantB. ClamagirandC. PotierM.C. Role of cholesterol metabolism in the pathogenesis of Alzheimerʼs disease.Curr. Opin. Clin. Nutr. Metab. Care201417431932310.1097/MCO.000000000000006924839952
     [Google Scholar]
  25. ClineE.N. BiccaM.A. ViolaK.L. KleinW.L. The amyloid-β oligomer hypothesis: Beginning of the third decade.J. Alzheimers Dis.201864s1S567S61010.3233/JAD‑17994129843241
     [Google Scholar]
  26. NixonR.A. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer’s disease: Inseparable partners in a multifactorial disease.FASEB J.20173172729274310.1096/fj.20170035928663518
     [Google Scholar]
  27. ZetterbergH. MattssonN. Understanding the cause of sporadic Alzheimer’s disease.Expert Rev. Neurother.201414662163010.1586/14737175.2014.91574024852227
     [Google Scholar]
  28. GiannakopoulosP. HerrmannF.R. BussièreT. BourasC. KövariE. PerlD.P. MorrisonJ.H. GoldG. HofP.R. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease.Neurology20036091495150010.1212/01.WNL.0000063311.58879.0112743238
     [Google Scholar]
  29. MuckeL. Alzheimer’s disease.Nature2009461726689589710.1038/461895a19829367
     [Google Scholar]
  30. HampelH. MesulamM.M. CuelloA.C. FarlowM.R. GiacobiniE. GrossbergG.T. KhachaturianA.S. VergalloA. CavedoE. SnyderP.J. KhachaturianZ.S. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease.Brain201814171917193310.1093/brain/awy13229850777
     [Google Scholar]
  31. MesulamM.M. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer’s disease.J. Comp. Neurol.2013521184124414410.1002/cne.2341523852922
     [Google Scholar]
  32. SchliebsR. ArendtT. The cholinergic system in aging and neuronal degeneration.Behav. Brain Res.2011221255556310.1016/j.bbr.2010.11.05821145918
     [Google Scholar]
  33. BeachT.G. KuoY.M. SpiegelK. EmmerlingM.R. SueL.I. KokjohnK. RoherA.E. The cholinergic deficit coincides with Aβ deposition at the earliest histopathologic stages of Alzheimer disease.J. Neuropathol. Exp. Neurol.200059430831310.1093/jnen/59.4.30810759186
     [Google Scholar]
  34. ViolaK.L. KleinW.L. Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis.Acta Neuropathol.2015129218320610.1007/s00401‑015‑1386‑325604547
     [Google Scholar]
  35. BraakH. TrediciK.D. RübU. de VosR.A.I. Jansen SteurE.N.H. BraakE. Staging of brain pathology related to sporadic Parkinson’s disease.Neurobiol. Aging200324219721110.1016/S0197‑4580(02)00065‑912498954
     [Google Scholar]
  36. SingletonA. FarrerM JohnsonJ Alpha-synuclein locus triplication causes Parkinson's disease.Science20033025646841
     [Google Scholar]
  37. DawsonT.M. DawsonV.L. The role of parkin in familial and sporadic Parkinson’s disease.Mov. Disord.201025S1S32S3910.1002/mds.2279820187240
     [Google Scholar]
  38. ValenteE.M. Abou-SleimanP.M. CaputoV. MuqitM.M.K. HarveyK. GispertS. AliZ. Del TurcoD. BentivoglioA.R. HealyD.G. AlbaneseA. NussbaumR. González-MaldonadoR. DellerT. SalviS. CortelliP. GilksW.P. LatchmanD.S. HarveyR.J. DallapiccolaB. AuburgerG. WoodN.W. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1.Science200430456741158116010.1126/science.109628415087508
     [Google Scholar]
  39. ShinJ.H. KoH.S. KangH. LeeY. LeeY.I. PletinkovaO. TroconsoJ.C. DawsonV.L. DawsonT.M. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson’s disease.Cell2011144568970210.1016/j.cell.2011.02.01021376232
     [Google Scholar]
  40. ZhengB. LiaoZ LocascioJJ PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.Sci Transl Med.201025252ra73
     [Google Scholar]
  41. ZhaoA. LiuN. YaoM. ZhangY. YaoZ. FengY. LiuJ. ZhouG. A review of neuroprotective effects and mechanisms of ginsenosides from Panax ginseng in treating Ischemic stroke.Front. Pharmacol.20221394675210.3389/fphar.2022.94675235873557
     [Google Scholar]
  42. FeuersteinG.Z. ChavezJ. Translational medicine for stroke drug discovery: The pharmaceutical industry perspective.Stroke2009403_suppl_1S121S12510.1161/STROKEAHA.108.53510419064772
     [Google Scholar]
  43. FamakinB. The immune response to acute focal cerebral ischemia and associated post-stroke immunodepression: A focused review.Aging Dis.20145530732610.14336/ad.2014.050030725276490
     [Google Scholar]
  44. del ZoppoG. GinisI. HallenbeckJ.M. IadecolaC. WangX. FeuersteinG.Z. Inflammation and stroke: Putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia.Brain Pathol.20001019511210.1111/j.1750‑3639.2000.tb00247.x10668900
     [Google Scholar]
  45. De SimoniM.G. MiliaP. BarbaM. LuigiA.D. ParnettiL. GallaiV. The inflammatory response in cerebral ischemia: Focus on cytokines in stroke patients.Clin. Exp. Hypertens.2002247-853554210.1081/CEH‑12001533012450229
     [Google Scholar]
  46. MarisJ.M. Recent advances in neuroblastoma.N. Engl. J. Med.2010362232202221110.1056/NEJMra080457720558371
     [Google Scholar]
  47. MatthayK.K. MarisJ.M. SchleiermacherG. NakagawaraA. MackallC.L. DillerL. WeissW.A. Neuroblastoma.Nat. Rev. Dis. Primers2016211607810.1038/nrdp.2016.78
     [Google Scholar]
  48. CohnS.L. PearsonA.D.J. LondonW.B. MonclairT. AmbrosP.F. BrodeurG.M. FaldumA. HeroB. IeharaT. MachinD. MosseriV. SimonT. GaraventaA. CastelV. MatthayK.K. The international neuroblastoma risk group (INRG) classification system: An INRG task force report.J. Clin. Oncol.200927228929710.1200/JCO.2008.16.678519047291
     [Google Scholar]
  49. PerriP. PonzoniM. CorriasM.V. CeccheriniI. CandianiS. BachettiT. A focus on regulatory networks linking MicroRNAs, transcription factors and target genes in neuroblastoma.Cancers (Basel)20211321552810.3390/cancers1321552834771690
     [Google Scholar]
  50. LongoL. ToniniG.P. CeccheriniI. PerriP. Oligogenic inheritance in neuroblastoma.Cancer Lett.20052281-2656910.1016/j.canlet.2004.12.05215923081
     [Google Scholar]
  51. AlahmadiH. CroulS.E. Pathology and genetics of meningiomas. Seminars in diagnostic pathology.Elsevier201110.1053/j.semdp.2011.01.002
     [Google Scholar]
  52. GladsonC.L. PraysonR.A. LiuW.M. The pathobiology of glioma tumors.Annu. Rev. Pathol.201051335010.1146/annurev‑pathol‑121808‑10210919737106
     [Google Scholar]
  53. SchwartzbaumJ.A. FisherJ.L. AldapeK.D. WrenschM. Epidemiology and molecular pathology of glioma.Nat. Clin. Pract. Neurol.20062949450310.1038/ncpneuro028916932614
     [Google Scholar]
  54. BorowskaA. JóźwiakJ. Medulloblastoma: Molecular pathways and histopathological classification.Arch. Med. Sci.20163365966610.5114/aoms.2016.5993927279861
     [Google Scholar]
  55. MolitchM.E. Diagnosis and treatment of pituitary adenomas: A review.JAMA2017317551652410.1001/jama.2016.1969928170483
     [Google Scholar]
  56. DworakowskaD. GrossmanA.B. The pathophysiology of pituitary adenomas.Best Pract. Res. Clin. Endocrinol. Metab.200923552554110.1016/j.beem.2009.05.00419945021
     [Google Scholar]
  57. HanJ. YeM. XuM. SunJ. WangB. GuoD. Characterization of flavonoids in the traditional Chinese herbal medicine-Huangqin by liquid chromatography coupled with electrospray ionization mass spectrometry.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.2007848235536210.1016/j.jchromb.2006.10.06117118721
     [Google Scholar]
  58. Li-WeberM. New therapeutic aspects of flavones: The anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin.Cancer Treat. Rev.2009351576810.1016/j.ctrv.2008.09.00519004559
     [Google Scholar]
  59. LeeG.S. KangT.J. Cuttlebone shows anti-inflammatory activity via suppression of NF-κB activation in LPS-induced RAW 264.7 macrophages.Yakhak Hoeji2021651414510.17480/psk.2021.65.1.41
     [Google Scholar]
  60. AlamM.B. ChowdhuryN.S. SohrabM.H. RanaM.S. HasanC.M. LeeS.H. Cerevisterol alleviates inflammation via suppression of MAPK/NF-κB/AP-1 and activation of the Nrf2/HO-1 signaling cascade.Biomolecules202010219910.3390/biom1002019932013140
     [Google Scholar]
  61. HuangX.W. XuY. SuiX. LinH. XuJ.M. HanD. YeD.D. LvG.F. LiuY.X. QuX.B. DuanM.H. Scutellarein suppresses Aβ-induced memory impairment via inhibition of the NF-κB pathway in vivo and in vitro. Oncol. Lett.20191765581558910.3892/ol.2019.1027431186780
     [Google Scholar]
  62. ChaudharyA.K. Harminder SinghV. A Review on the taxonomy, ethnobotany, chemistry and pharmacology of Oroxylum indicum vent.Indian J. Pharm. Sci.201173548349010.4103/0250‑474X.9898122923859
     [Google Scholar]
  63. TangH. TangY. LiN. ShiQ. GuoJ. ShangE. DuanJ. Neuroprotective effects of scutellarin and scutellarein on repeatedly cerebral ischemia–reperfusion in rats.Pharmacol. Biochem. Behav.2014118515910.1016/j.pbb.2014.01.00324423938
     [Google Scholar]
  64. ByeonS.E. YiYS OhJ The role of Src kinase in macrophage-mediated inflammatory responses.Mediators Inflamm.2012201251292610.1155/2012/512926
     [Google Scholar]
  65. QianL.H. LiN.G. TangY.P. ZhangL. TangH. WangZ.J. LiuL. SongS.L. GuoJ.M. DingA.W. Synthesis and bio-activity evaluation of scutellarein as a potent agent for the therapy of ischemic cerebrovascular disease.Int. J. Mol. Sci.201112118208821610.3390/ijms1211820822174659
     [Google Scholar]
  66. LiuZ.Q. Chemical methods to evaluate antioxidant ability.Chem. Rev.2010110105675569110.1021/cr900302x20939615
     [Google Scholar]
  67. PavlicaS. GebhardtR. Protective effects of flavonoids and two metabolites against oxidative stress in neuronal PC12 cells.Life Sci.2010863-4798610.1016/j.lfs.2009.10.01719891977
     [Google Scholar]
  68. WangH. GaoX.D. ZhouG.C. CaiL. YaoW.B. In vitro and in vivo antioxidant activity of aqueous extract from Choerospondias axillaris fruit.Food Chem.2008106388889510.1016/j.foodchem.2007.05.068
     [Google Scholar]
  69. RongY. DistelhorstC.W. Bcl-2 protein family members: Versatile regulators of calcium signaling in cell survival and apoptosis.Annu. Rev. Physiol.2008701739110.1146/annurev.physiol.70.021507.10585217680735
     [Google Scholar]
  70. YouL. ZhuH. WangC. WangF. LiY. LiY. WangY. HeB. Scutellarin inhibits Hela cell growth and glycolysis by inhibiting the activity of pyruvate kinase M2.Bioorg. Med. Chem. Lett.201727245404540810.1016/j.bmcl.2017.11.01129157862
     [Google Scholar]
  71. WangW. LiuX. GuoX. QuanH. Mitofusin-2 triggers cervical carcinoma cell hela apoptosis via mitochondrial pathway in mouse model.Cell. Physiol. Biochem.2018461698110.1159/00048841029587277
     [Google Scholar]
  72. ShiL. WuY. LvD. FengL. Scutellarein selectively targets multiple myeloma cells by increasing mitochondrial superoxide production and activating intrinsic apoptosis pathway.Biomed. Pharmacother.20191092109211810.1016/j.biopha.2018.09.02430551468
     [Google Scholar]
  73. BurnsA. Citicoline in the treatment of acute ischaemic stroke: An international, randomised, multicentre, placebo-controlled study (ICTUS trial).Lancet20203961024841344632738937
     [Google Scholar]
  74. HardyJ. SelkoeD.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics.Science2002297558035335610.1126/science.1072994
     [Google Scholar]
  75. ThambisettyM. AnY. TanakaT. Alzheimer's disease risk genes and the age-at-onset phenotype.Neurobiol Aging201334112696.e1-2696.e510.1016/j.neurobiolaging.2013.05.028
     [Google Scholar]
  76. TannenbergR.K. ScottH.L. TannenbergA.E.G. DoddP.R. Selective loss of synaptic proteins in Alzheimer’s disease: Evidence for an increased severity with APOE ɛ4.Neurochem. Int.200649763163910.1016/j.neuint.2006.05.00416814428
     [Google Scholar]
  77. QuerfurthH.W. LaFerlaF.M. Alzheimer’s disease.N. Engl. J. Med.2010362432934410.1056/NEJMra090914220107219
     [Google Scholar]
  78. LoewenC.A. FeanyM.B. The unfolded protein response protects from tau neurotoxicity in vivo.PLoS One201059e1308410.1371/journal.pone.001308420927324
     [Google Scholar]
  79. HardyJ.A. HigginsG.A. Alzheimer’s disease: The amyloid cascade hypothesis.Science1992256505418418510.1126/science.15660671566067
     [Google Scholar]
  80. ChételatG. Aβ-independent processes—Rethinking preclinical AD.Nat. Rev. Neurol.20139312312410.1038/nrneurol.2013.2123399647
     [Google Scholar]
  81. TarozziA. MorroniF. MerliccoA. BolondiC. TetiG. FalconiM. Cantelli-FortiG. HreliaP. Neuroprotective effects of cyanidin 3-O-glucopyranoside on amyloid beta (25–35) oligomer-induced toxicity.Neurosci. Lett.20104732727610.1016/j.neulet.2010.02.00620152881
     [Google Scholar]
  82. LiuY. DarguschR. BanhC. MillerC.A. SchubertD. Detecting bioactive amyloid β peptide species in Alzheimer’s disease.J. Neurochem.200491364865610.1111/j.1471‑4159.2004.02751.x15485495
     [Google Scholar]
  83. RizouA.E.I. NasiG.I. PaikopoulosY. BezantakouD.S. VrailaK.D. SpatharasP.M. DimakiV.D. PapandreouN.C. LamariF.N. ChondrogianniN. IconomidouV.A. A multilevel study of eupatorin and scutellarein as anti-amyloid agents in Alzheimer’s disease.Biomedicines2023115135710.3390/biomedicines1105135737239029
     [Google Scholar]
  84. TarsyD. Treatment of Parkinson's disease: A 64-year-old man with motor complications of advanced Parkinson disease.JAMA2012307212305231410.1001/jama.2012.482922706836
     [Google Scholar]
  85. DorseyE.R. ElbazA. NicholsE. AbbasiN. Abd-AllahF. AbdelalimA. AdsuarJ.C. AnshaM.G. BrayneC. ChoiJ-Y.J. Collado-MateoD. DahodwalaN. DoH.P. EdessaD. EndresM. FereshtehnejadS-M. ForemanK.J. GankpeF.G. GuptaR. HamidiS. HankeyG.J. HayS.I. HegazyM.I. HibstuD.T. KasaeianA. KhaderY. KhalilI. KhangY-H. KimY.J. KokuboY. LogroscinoG. MassanoJ. Mohamed IbrahimN. MohammedM.A. MohammadiA. Moradi-LakehM. NaghaviM. NguyenB.T. NirayoY.L. OgboF.A. OwolabiM.O. PereiraD.M. PostmaM.J. QorbaniM. RahmanM.A. RobaK.T. SafariH. SafiriS. SatpathyM. SawhneyM. ShafieesabetA. ShiferawM.S. SmithM. SzoekeC.E.I. Tabarés-SeisdedosR. TruongN.T. UkwajaK.N. VenketasubramanianN. VillafainaS. weldegwergsK. WestermanR. WijeratneT. WinklerA.S. XuanB.T. YonemotoN. FeiginV.L. VosT. MurrayC.J.L. Global, regional, and national burden of Parkinson’s disease, 1990–2016: A systematic analysis for the global burden of disease study 2016.Lancet Neurol.2018171193995310.1016/S1474‑4422(18)30295‑330287051
     [Google Scholar]
  86. DawsonT.M. DawsonV.L. Molecular pathways of neurodegeneration in Parkinson’s disease.Science2003302564681982210.1126/science.108775314593166
     [Google Scholar]
  87. CalneS. SchoenbergB. MartinW. UittiR.J. SpencerP. CalneD.B. Familial Parkinson’s disease: Possible role of environmental factors.Can. J. Neurol. Sci.198714330330510.1017/S03171671000266643664372
     [Google Scholar]
  88. SchoenbergB.S. Environmental risk factors for Parkinson’s disease: The epidemiologic evidence.Can. J. Neurol. Sci.198714S3Suppl.40741310.1017/S03171671000378113315146
     [Google Scholar]
  89. SungV.W. NicholasA.P. Nonmotor symptoms in Parkinson’s disease: Expanding the view of Parkinson’s disease beyond a pure motor, pure dopaminergic problem.Neurol. Clin.2013313Suppl.S1S1610.1016/j.ncl.2013.04.01323931951
     [Google Scholar]
  90. PolymeropoulosM.H. LavedanC LeroyE Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.Science199727653212045204710.1126/science.276.5321.2045
     [Google Scholar]
  91. KrügerR. KuhnW. MüllerT. WoitallaD. GraeberM. KöselS. PrzuntekH. EpplenJ.T. SchölsL. RiessO. AlaSOPro mutation in the gene encoding α-synuclein in Parkinson’s disease.Nat. Genet.199818210610810.1038/ng0298‑1069462735
     [Google Scholar]
  92. BekrisL.M. MataI.F. ZabetianC.P. The genetics of Parkinson disease.J. Geriatr. Psychiatry Neurol.201023422824210.1177/089198871038357220938043
     [Google Scholar]
  93. GuldbergH.C. MarsdenC.A. Catechol-O-methyl transferase: Pharmacological aspects and physiological role.Pharmacol. Rev.19752721352061103160
     [Google Scholar]
  94. KopinI.J. Catecholamine metabolism: Basic aspects and clinical significance.Pharmacol. Rev.19853743333643915090
     [Google Scholar]
  95. MännistöP.T. KaakkolaS. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.Pharmacol. Rev.199951459362810581325
     [Google Scholar]
  96. KissL.E. Soares-da-SilvaP. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.J. Med. Chem.201457218692871710.1021/jm500572b25080080
     [Google Scholar]
  97. PalmaP.N. BonifácioM.J. LoureiroA.I. WrightL.C. LearmonthD.A. Soares-da-SilvaP. Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor.Drug Metab. Dispos.200331325025810.1124/dmd.31.3.25012584150
     [Google Scholar]
  98. CaruanaM. HögenT. LevinJ. HillmerA. GieseA. VassalloN. Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds.FEBS Lett.201158581113112010.1016/j.febslet.2011.03.04621443877
     [Google Scholar]
  99. ZhaoD.F. FanY.F. WangF.Y. HouF.B. GonzalezF.J. LiS.Y. WangP. XiaY.L. GeG.B. YangL. Discovery and characterization of naturally occurring potent inhibitors of catechol- O -methyltransferase from herbal medicines.RSC Advances20211117103851039210.1039/D0RA10425F35423513
     [Google Scholar]
  100. SubediL. GaireB.P. Phytochemicals as regulators of microglia/ macrophages activation in cerebral ischemia.Pharmacol. Res.202116510541910.1016/j.phrs.2021.10541933450385
     [Google Scholar]
  101. DonnanG.A. FisherM. MacleodM. DavisS.M. Secondary prevention of stroke – Authors’ reply.Lancet20083729643103610.1016/S0140‑6736(08)61439‑7
     [Google Scholar]
  102. MartzD. BeerM. BetzA.L. Dimethylthiourea reduces ischemic brain edema without affecting cerebral blood flow.J. Cereb. Blood Flow Metab.199010335235710.1038/jcbfm.1990.642109751
     [Google Scholar]
  103. LeeJ.M. GrabbM.C. ZipfelG.J. ChoiD.W. Brain tissue responses to ischemia.J. Clin. Invest.2000106672373110.1172/JCI1100310995780
     [Google Scholar]
  104. JayarajR.L. AzimullahS. BeiramR. JalalF.Y. RosenbergG.A. Neuroinflammation: Friend and foe for ischemic stroke.J. Neuroinflammation201916114210.1186/s12974‑019‑1516‑231291966
     [Google Scholar]
  105. CuzzocreaS. RileyD.P. CaputiA.P. SalveminiD. Antioxidant therapy: A new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury.Pharmacol. Rev.200153113515911171943
     [Google Scholar]
  106. LakhanS.E. KirchgessnerA. HoferM. Inflammatory mechanisms in ischemic stroke: Therapeutic approaches.J. Transl. Med.2009719710.1186/1479‑5876‑7‑9719919699
     [Google Scholar]
  107. YangZ.Z. LiJ. LiS.X. FengW. WangH. Effect of ginkgolide B on striatal extracellular amino acids in middle cerebral artery occluded rats.J. Ethnopharmacol.2011136111712210.1016/j.jep.2011.04.02721527331
     [Google Scholar]
  108. EvansP.H. Free radicals in brain metabolism and pathology.Br. Med. Bull.199349357758710.1093/oxfordjournals.bmb.a0726328221024
     [Google Scholar]
  109. FujimuraM. TominagaT. ChanP.H. Neuroprotective effect of an antioxidant in ischemic brain injury: Involvement of neuronal apoptosis.Neurocrit. Care20052105906610.1385/NCC:2:1:05916174972
     [Google Scholar]
  110. ChoiD.W. RothmanS.M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death.Annu. Rev. Neurosci.199013117118210.1146/annurev.ne.13.030190.0011311970230
     [Google Scholar]
  111. ZhangY. ChenQ GuWD DingHZ ZengYM Effects of erigeron on ATP content and release of excitatory amino-acids of the hippocampus after cerebral ischemia/reperfusion injury in gerbils.Jiangsu Med J200531843847
     [Google Scholar]
  112. SmallD.L. BuchanA.M. Mechanisms of cerebral ischemia: Intracellular cascades and therapeutic interventions.J. Cardiothorac. Vasc. Anesth.199610113914610.1016/S1053‑0770(96)80189‑38634379
     [Google Scholar]
  113. CheungN-K.V. CohnS.L. Neuroblastoma.Springer Science & Business Media200510.1007/b137762
     [Google Scholar]
  114. ZafarA. WangW. LiuG. WangX. XianW. McKeonF. FosterJ. ZhouJ. ZhangR. Molecular targeting therapies for neuroblastoma: Progress and challenges.Med. Res. Rev.2021412961102110.1002/med.2175033155698
     [Google Scholar]
  115. LanzkowskyP. LiptonJ. FishJ.D. Lanzkowsky’s manual of pediatric hematology and oncology.Elsevier2016
     [Google Scholar]
  116. SmithV. FosterJ. High-risk neuroblastoma treatment review.Children (Basel)20185911410.3390/children509011430154341
     [Google Scholar]
  117. KholodenkoIV KalinovskyDV DoroninI DeyevSM KholodenkoRV Neuroblastoma origin and therapeutic targets for immunotherapy.J Immunol Res.20182018739426810.1155/2018/7394268
     [Google Scholar]
  118. LondonW.B. CastleberryR.P. MatthayK.K. LookA.T. SeegerR.C. ShimadaH. ThornerP. BrodeurG. MarisJ.M. ReynoldsC.P. CohnS.L. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the children’s oncology group.J. Clin. Oncol.200523276459646510.1200/JCO.2005.05.57116116153
     [Google Scholar]
  119. CheungN.K.V. DyerM.A. Neuroblastoma: Developmental biology, cancer genomics and immunotherapy.Nat. Rev. Cancer201313639741110.1038/nrc352623702928
     [Google Scholar]
  120. KovalevichJ. LangfordD. Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology.Methods Mol Biol.20131078921
     [Google Scholar]
  121. BiedlerJ.L. Roffler-TarlovS. SchachnerM. FreedmanL.S. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones.Cancer Res.19783811 Pt 13751375729704
     [Google Scholar]
  122. XieH.R. HuL.S. LiG.Y. SH-SY5Y human neuroblastoma cell line: In vitro cell model of dopaminergic neurons in Parkinson’s disease.Chin. Med. J. (Engl.)201012381086109220497720
     [Google Scholar]
  123. PresgravesS.P. AhmedT. BorwegeS. JoyceJ.N. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists.Neurotox. Res.20035857959810.1007/BF0303317815111235
     [Google Scholar]
  124. ZhaiC.Y. FanJ.S. ZhangR.P. Scutellarein treats neuroblastoma by regulating the expression of multiple targets.Ibrain202410334535510.1002/ibra.1210039346787
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128336901241125092132
Loading
Therapeutic Role of Scutellarein in Neurological Disorders
Curr. Pharm. Des. 31, 1583 (2025); https://doi.org/10.2174/0113816128336901241125092132
/content/journals/cpd/10.2174/0113816128336901241125092132
/content/journals/cpd/10.2174/0113816128336901241125092132
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Alzheimer’s disease; antioxidant; cerebral ischemia; neuroblastoma; neurodegenerative diseases; Parkinson’s disease; Scutellarein

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test